Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia

Zhengshan Chen, Seyedmehdi Shojaee, Maike Buchner, Huimin Geng, Jae Woong Lee, Lars Klemm, Björn Titz, Thomas G. Graeber, Eugene Park, Ying Xim Tan, Anne Satterthwaite, Elisabeth M. Paietta, Stephen P. Hunger, Cheryl L. Willman, Ari Melnick, Mignon L. Loh, Jae U. Jung, John E. Coligan, Silvia Bolland, Tak W. MakAndre Limnander, Hassan Jumaa, Michael Reth, Arthur Weiss, Clifford A. Lowell, Markus Müschen

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

B cells are selected for an intermediate level of B-cell antigen receptor (BCR) signalling strength: attenuation below minimum (for example, non-functional BCR) or hyperactivation above maximum (for example, self-reactive BCR) thresholds of signalling strength causes negative selection. In ∼25% of cases, acute lymphoblastic leukaemia (ALL) cells carry the oncogenic BCR-ABL1 tyrosine kinase (Philadelphia chromosome positive), which mimics constitutively active pre-BCR signalling. Current therapeutic approaches are largely focused on the development of more potent tyrosine kinase inhibitors to suppress oncogenic signalling below a minimum threshold for survival. We tested the hypothesis that targeted hyperactivation - above a maximum threshold - will engage a deletional checkpoint for removal of self-reactive B cells and selectively kill ALL cells. Here we find, by testing various components of proximal pre-BCR signalling in mouse BCR-ABL1 cells, that an incremental increase of Syk tyrosine kinase activity was required and sufficient to induce cell death. Hyperactive Syk was functionally equivalent to acute activation of a self-reactive BCR on ALL cells. Despite oncogenic transformation, this basic mechanism of negative selection was still functional in ALL cells. Unlike normal pre-B cells, patient-derived ALL cells express the inhibitory receptors PECAM1, CD300A and LAIR1 at high levels. Genetic studies revealed that Pecam1, Cd300a and Lair1 are critical to calibrate oncogenic signalling strength through recruitment of the inhibitory phosphatases Ptpn6 (ref. 7) and Inpp5d (ref. 8). Using a novel small-molecule inhibitor of INPP5D (also known as SHIP1), we demonstrated that pharmacological hyperactivation of SYK and engagement of negative B-cell selection represents a promising new strategy to overcome drug resistance in human ALL.

Original languageEnglish (US)
Pages (from-to)357-361
Number of pages5
JournalNature
Volume521
Issue number7552
DOIs
StatePublished - May 21 2015

Fingerprint

B-Cell Antigen Receptors
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Lymphocytes
Pre-B Cell Receptors
Protein-Tyrosine Kinases
Philadelphia Chromosome
B-Lymphoid Precursor Cells
Phosphoric Monoester Hydrolases
Drug Resistance
Cell Death
Pharmacology
Survival

ASJC Scopus subject areas

  • General

Cite this

Chen, Z., Shojaee, S., Buchner, M., Geng, H., Lee, J. W., Klemm, L., ... Müschen, M. (2015). Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature, 521(7552), 357-361. https://doi.org/10.1038/nature14231

Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. / Chen, Zhengshan; Shojaee, Seyedmehdi; Buchner, Maike; Geng, Huimin; Lee, Jae Woong; Klemm, Lars; Titz, Björn; Graeber, Thomas G.; Park, Eugene; Tan, Ying Xim; Satterthwaite, Anne; Paietta, Elisabeth M.; Hunger, Stephen P.; Willman, Cheryl L.; Melnick, Ari; Loh, Mignon L.; Jung, Jae U.; Coligan, John E.; Bolland, Silvia; Mak, Tak W.; Limnander, Andre; Jumaa, Hassan; Reth, Michael; Weiss, Arthur; Lowell, Clifford A.; Müschen, Markus.

In: Nature, Vol. 521, No. 7552, 21.05.2015, p. 357-361.

Research output: Contribution to journalArticle

Chen, Z, Shojaee, S, Buchner, M, Geng, H, Lee, JW, Klemm, L, Titz, B, Graeber, TG, Park, E, Tan, YX, Satterthwaite, A, Paietta, EM, Hunger, SP, Willman, CL, Melnick, A, Loh, ML, Jung, JU, Coligan, JE, Bolland, S, Mak, TW, Limnander, A, Jumaa, H, Reth, M, Weiss, A, Lowell, CA & Müschen, M 2015, 'Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia', Nature, vol. 521, no. 7552, pp. 357-361. https://doi.org/10.1038/nature14231
Chen Z, Shojaee S, Buchner M, Geng H, Lee JW, Klemm L et al. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 2015 May 21;521(7552):357-361. https://doi.org/10.1038/nature14231
Chen, Zhengshan ; Shojaee, Seyedmehdi ; Buchner, Maike ; Geng, Huimin ; Lee, Jae Woong ; Klemm, Lars ; Titz, Björn ; Graeber, Thomas G. ; Park, Eugene ; Tan, Ying Xim ; Satterthwaite, Anne ; Paietta, Elisabeth M. ; Hunger, Stephen P. ; Willman, Cheryl L. ; Melnick, Ari ; Loh, Mignon L. ; Jung, Jae U. ; Coligan, John E. ; Bolland, Silvia ; Mak, Tak W. ; Limnander, Andre ; Jumaa, Hassan ; Reth, Michael ; Weiss, Arthur ; Lowell, Clifford A. ; Müschen, Markus. / Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. In: Nature. 2015 ; Vol. 521, No. 7552. pp. 357-361.
@article{a74f6d24e1c74117be5dbdde8c54dbc2,
title = "Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia",
abstract = "B cells are selected for an intermediate level of B-cell antigen receptor (BCR) signalling strength: attenuation below minimum (for example, non-functional BCR) or hyperactivation above maximum (for example, self-reactive BCR) thresholds of signalling strength causes negative selection. In ∼25{\%} of cases, acute lymphoblastic leukaemia (ALL) cells carry the oncogenic BCR-ABL1 tyrosine kinase (Philadelphia chromosome positive), which mimics constitutively active pre-BCR signalling. Current therapeutic approaches are largely focused on the development of more potent tyrosine kinase inhibitors to suppress oncogenic signalling below a minimum threshold for survival. We tested the hypothesis that targeted hyperactivation - above a maximum threshold - will engage a deletional checkpoint for removal of self-reactive B cells and selectively kill ALL cells. Here we find, by testing various components of proximal pre-BCR signalling in mouse BCR-ABL1 cells, that an incremental increase of Syk tyrosine kinase activity was required and sufficient to induce cell death. Hyperactive Syk was functionally equivalent to acute activation of a self-reactive BCR on ALL cells. Despite oncogenic transformation, this basic mechanism of negative selection was still functional in ALL cells. Unlike normal pre-B cells, patient-derived ALL cells express the inhibitory receptors PECAM1, CD300A and LAIR1 at high levels. Genetic studies revealed that Pecam1, Cd300a and Lair1 are critical to calibrate oncogenic signalling strength through recruitment of the inhibitory phosphatases Ptpn6 (ref. 7) and Inpp5d (ref. 8). Using a novel small-molecule inhibitor of INPP5D (also known as SHIP1), we demonstrated that pharmacological hyperactivation of SYK and engagement of negative B-cell selection represents a promising new strategy to overcome drug resistance in human ALL.",
author = "Zhengshan Chen and Seyedmehdi Shojaee and Maike Buchner and Huimin Geng and Lee, {Jae Woong} and Lars Klemm and Bj{\"o}rn Titz and Graeber, {Thomas G.} and Eugene Park and Tan, {Ying Xim} and Anne Satterthwaite and Paietta, {Elisabeth M.} and Hunger, {Stephen P.} and Willman, {Cheryl L.} and Ari Melnick and Loh, {Mignon L.} and Jung, {Jae U.} and Coligan, {John E.} and Silvia Bolland and Mak, {Tak W.} and Andre Limnander and Hassan Jumaa and Michael Reth and Arthur Weiss and Lowell, {Clifford A.} and Markus M{\"u}schen",
year = "2015",
month = "5",
day = "21",
doi = "10.1038/nature14231",
language = "English (US)",
volume = "521",
pages = "357--361",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7552",

}

TY - JOUR

T1 - Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia

AU - Chen, Zhengshan

AU - Shojaee, Seyedmehdi

AU - Buchner, Maike

AU - Geng, Huimin

AU - Lee, Jae Woong

AU - Klemm, Lars

AU - Titz, Björn

AU - Graeber, Thomas G.

AU - Park, Eugene

AU - Tan, Ying Xim

AU - Satterthwaite, Anne

AU - Paietta, Elisabeth M.

AU - Hunger, Stephen P.

AU - Willman, Cheryl L.

AU - Melnick, Ari

AU - Loh, Mignon L.

AU - Jung, Jae U.

AU - Coligan, John E.

AU - Bolland, Silvia

AU - Mak, Tak W.

AU - Limnander, Andre

AU - Jumaa, Hassan

AU - Reth, Michael

AU - Weiss, Arthur

AU - Lowell, Clifford A.

AU - Müschen, Markus

PY - 2015/5/21

Y1 - 2015/5/21

N2 - B cells are selected for an intermediate level of B-cell antigen receptor (BCR) signalling strength: attenuation below minimum (for example, non-functional BCR) or hyperactivation above maximum (for example, self-reactive BCR) thresholds of signalling strength causes negative selection. In ∼25% of cases, acute lymphoblastic leukaemia (ALL) cells carry the oncogenic BCR-ABL1 tyrosine kinase (Philadelphia chromosome positive), which mimics constitutively active pre-BCR signalling. Current therapeutic approaches are largely focused on the development of more potent tyrosine kinase inhibitors to suppress oncogenic signalling below a minimum threshold for survival. We tested the hypothesis that targeted hyperactivation - above a maximum threshold - will engage a deletional checkpoint for removal of self-reactive B cells and selectively kill ALL cells. Here we find, by testing various components of proximal pre-BCR signalling in mouse BCR-ABL1 cells, that an incremental increase of Syk tyrosine kinase activity was required and sufficient to induce cell death. Hyperactive Syk was functionally equivalent to acute activation of a self-reactive BCR on ALL cells. Despite oncogenic transformation, this basic mechanism of negative selection was still functional in ALL cells. Unlike normal pre-B cells, patient-derived ALL cells express the inhibitory receptors PECAM1, CD300A and LAIR1 at high levels. Genetic studies revealed that Pecam1, Cd300a and Lair1 are critical to calibrate oncogenic signalling strength through recruitment of the inhibitory phosphatases Ptpn6 (ref. 7) and Inpp5d (ref. 8). Using a novel small-molecule inhibitor of INPP5D (also known as SHIP1), we demonstrated that pharmacological hyperactivation of SYK and engagement of negative B-cell selection represents a promising new strategy to overcome drug resistance in human ALL.

AB - B cells are selected for an intermediate level of B-cell antigen receptor (BCR) signalling strength: attenuation below minimum (for example, non-functional BCR) or hyperactivation above maximum (for example, self-reactive BCR) thresholds of signalling strength causes negative selection. In ∼25% of cases, acute lymphoblastic leukaemia (ALL) cells carry the oncogenic BCR-ABL1 tyrosine kinase (Philadelphia chromosome positive), which mimics constitutively active pre-BCR signalling. Current therapeutic approaches are largely focused on the development of more potent tyrosine kinase inhibitors to suppress oncogenic signalling below a minimum threshold for survival. We tested the hypothesis that targeted hyperactivation - above a maximum threshold - will engage a deletional checkpoint for removal of self-reactive B cells and selectively kill ALL cells. Here we find, by testing various components of proximal pre-BCR signalling in mouse BCR-ABL1 cells, that an incremental increase of Syk tyrosine kinase activity was required and sufficient to induce cell death. Hyperactive Syk was functionally equivalent to acute activation of a self-reactive BCR on ALL cells. Despite oncogenic transformation, this basic mechanism of negative selection was still functional in ALL cells. Unlike normal pre-B cells, patient-derived ALL cells express the inhibitory receptors PECAM1, CD300A and LAIR1 at high levels. Genetic studies revealed that Pecam1, Cd300a and Lair1 are critical to calibrate oncogenic signalling strength through recruitment of the inhibitory phosphatases Ptpn6 (ref. 7) and Inpp5d (ref. 8). Using a novel small-molecule inhibitor of INPP5D (also known as SHIP1), we demonstrated that pharmacological hyperactivation of SYK and engagement of negative B-cell selection represents a promising new strategy to overcome drug resistance in human ALL.

UR - http://www.scopus.com/inward/record.url?scp=84929635151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929635151&partnerID=8YFLogxK

U2 - 10.1038/nature14231

DO - 10.1038/nature14231

M3 - Article

C2 - 25799995

AN - SCOPUS:84929635151

VL - 521

SP - 357

EP - 361

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7552

ER -